The last 5 years have seen a host of new drugs approved for multiple myeloma, improving survival times for patients, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
The last 5 years have seen a host of new drugs approved for multiple myeloma, improving survival times for patients, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
Transcript
What has been the biggest change in the last 5 years in multiple myeloma treatment?
There have been so many changes in multiple myeloma. Number one, we’ve had a host of new drugs approved. Some of them are better drugs for the same mechanism of action. And some of them are new types of drugs and I’d say the new types of drugs have really been focused on immunotherapies, that being antibodies against specific proteins on the myeloma cells and that’s really changed the way we treat relapsed myeloma.
How have new multiple myeloma treatments impacted survival and other outcomes?
Well, we know that we’re doing a better job. We know that patients that are treated over the past 5 to 10 years are doing better than those treated before, and that’s really encouraging to us and part of that, most of that reason, is because of all these new drugs. We’re really thankful to all the patients for participating in clinical trials to help this along. I think that people who are diagnosed with myeloma now really can say that they’ll survive longer than those who had been diagnosed before. And that’s because of these new drugs.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More